Gilead-partnered Glympse snares $46.7M for their NASH-snooping biosensors

Since its emergence at JP Morgan six years ago, the NASH field has been held back not only by the question of how to treat the disease, but also by the question of how you diagnose it. It’s simply not that difficult to tell if a liver is fatty or scarred or in full-on cirrhosis.